Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Sponsor
European Paediatric Soft Tissue Sarcoma Study Group
Study ID
NCT00379457
Phase
PHASE3
Status
Unknown

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
N/A - 20 Years
Healthy Volunteers
Not accepted

Interventions

  • dactinomycin — BIOLOGICAL
  • carboplatin — DRUG
  • cyclophosphamide — DRUG
  • doxorubicin hydrochloride — DRUG
  • etoposide — DRUG
  • ifosfamide — DRUG
  • topotecan hydrochloride — DRUG
  • vincristine sulfate — DRUG
  • vinorelbine tartrate — DRUG
  • conventional surgery — PROCEDURE
  • radiation therapy — RADIATION

Study Details

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with nonmetastatic rhabdomyosarcoma.

Key Dates

Start date
Jun 30, 2006
Status verified
Jul 2009
Primary completion
May 31, 2011

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

Event-free survival

Related Studies